ProPhase Labs enters into ATM equity offering facility with WestPark Capital

ProPhase Labs, Inc.

ProPhase Labs entered an At-the-Market Sales Agreement with WestPark Capital on Oct 9, 2025, to sell common stock from time to time.
Agent receives 3.0% commission on gross proceeds; company reimburses certain expenses.
Sales made under existing effective S-3 registration statement (No. 333-283182) declared effective Nov 20, 2024.
Company is not obligated to sell any shares; may suspend or terminate agreement at any time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.